A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant.

MLA

Langley, Joanne M., et al. “A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant.” The Journal of Infectious Diseases, vol. 215, no. 1, Jan. 2017, pp. 24–33. EBSCOhost, https://doi.org/10.1093/infdis/jiw453.

APA

Langley, J. M., Aggarwal, N., Toma, A., Halperin, S. A., McNeil, S. A., Fissette, L., Dewé, W., Leyssen, M., Toussaint, J.-F., & Dieussaert, I. (2017). A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant. The Journal of Infectious Diseases, 215(1), 24–33. https://doi.org/10.1093/infdis/jiw453

Chicago

Langley, Joanne M, Naresh Aggarwal, Azhar Toma, Scott A Halperin, Shelly A McNeil, Laurence Fissette, Walthere Dewé, Maarten Leyssen, Jean-François Toussaint, and Ilse Dieussaert. 2017. “A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant.” The Journal of Infectious Diseases 215 (1): 24–33. doi:10.1093/infdis/jiw453.